The Experts below are selected from a list of 108 Experts worldwide ranked by ideXlab platform

Abolghasem Jouyban - One of the best experts on this subject based on the ideXlab platform.

  • solubility of Fluphenazine Decanoate in aqueous mixtures of polyethylene glycols 400 and 600 at various temperatures
    Fluid Phase Equilibria, 2014
    Co-Authors: Abolghasem Jouyban, Fleming Martinez, Vahid Panahiazar
    Abstract:

    Abstract The solubility of Fluphenazine Decanoate (FD) in aqueous binary mixtures of polyethylene glycols 400 (PEG 400) and 600 (PEG 600) at 298.0–318.0 K and atmospheric pressure along with some thermodynamic properties are reported. The previously trained version of the Jouyban–Acree model for PEG 400 + water, a recently proposed general cosolvency model employing partial solubility parameters, and a combination of the model with van’t Hoff equation were used to predict the solubility of FD in PEG 400 + water and PEG 600 + water at different temperatures. The results show that the Jouyban–Acree model can be used for solubility prediction of FD in aqueous mixtures of PEG 400 and PEG 600 at different temperatures. Densities of solute free aqueous mixtures of PEG 400 and PEG 600 along with their FD-saturated solutions are also reported.

  • thermodynamic studies of Fluphenazine Decanoate solubility in peg 200 water mixtures
    Fluid Phase Equilibria, 2012
    Co-Authors: Vahid Panahiazar, Somaieh Ahmadian, Fleming Martinez, William E Acree, Abolghasem Jouyban
    Abstract:

    Abstract The solubility of Fluphenazine Decanoate (FD) in binary mixtures of polyethylene glycol 200 (PEG 200) + water at the temperature range from 298.0 K to 318.0 K is reported. The previously trained version of the Jouyban–Acree model for PEG 200 + water, a recently proposed general cosolvency model employing partial solubility parameters, and a combination of the model with van’t Hoff equation were used to predict the solubility of FD in PEG 200 + water at different temperatures. The results show that the Jouyban–Acree model can be used for solubility prediction of FD in PEG 200 + water mixtures at different temperatures. The solubility data as a function of temperature were used to determine the thermodynamic properties of the dissolution process including Gibbs energy, enthalpy and entropy of the solution. An adapted version of the model is used to represent the thermodynamic properties of the solutions in the solvent mixtures and the obtained results were satisfactory. Densities of solute free PEG 200 + water and FD-saturated solutions are also reported.

  • Thermodynamic studies of Fluphenazine Decanoate solubility in PEG 200 + water mixtures
    Fluid Phase Equilibria, 2012
    Co-Authors: Vahid Panahi-azar, Somaieh Ahmadian, Fleming Martinez, William E Acree, Abolghasem Jouyban
    Abstract:

    Abstract The solubility of Fluphenazine Decanoate (FD) in binary mixtures of polyethylene glycol 200 (PEG 200) + water at the temperature range from 298.0 K to 318.0 K is reported. The previously trained version of the Jouyban–Acree model for PEG 200 + water, a recently proposed general cosolvency model employing partial solubility parameters, and a combination of the model with van’t Hoff equation were used to predict the solubility of FD in PEG 200 + water at different temperatures. The results show that the Jouyban–Acree model can be used for solubility prediction of FD in PEG 200 + water mixtures at different temperatures. The solubility data as a function of temperature were used to determine the thermodynamic properties of the dissolution process including Gibbs energy, enthalpy and entropy of the solution. An adapted version of the model is used to represent the thermodynamic properties of the solutions in the solvent mixtures and the obtained results were satisfactory. Densities of solute free PEG 200 + water and FD-saturated solutions are also reported.

  • thermodynamic studies of Fluphenazine Decanoate solubility in propylene glycol water mixtures and correlation with the jouyban acree model
    Fluid Phase Equilibria, 2011
    Co-Authors: Vahid Panahiazar, Fleming Martinez, William E Acree, Ali Shayanfar, Abolghasem Jouyban
    Abstract:

    Abstract Solubilities of Fluphenazine Decanoate (FD) in binary mixtures of propylene glycol + water (PG + W) at 293.2, 298.2, 303.2, 308.2, and 313.2 K are reported. The combination of Jouyban–Acree model and van’t Hoff equation is used to predict the solubility of FD in a given solvent mixture at different temperatures. The thermodynamic properties (enthalpy, entropy and Gibbs energy standard changes of solutions) for FD in PG + W mixtures are calculated from solubility data using the modified version of van’t Hoff and Gibbs equations. The results show that Jouyban–Acree model can predict the solubility of FD in PG + W mixtures as a function of temperature over the studied temperature range. The study represents the first time that thermodynamic properties of solutes dissolved in binary solvent mixtures have been described by the Jouyban–Acree model. The calculated values are in good agreement with the measured experimental data.

  • Thermodynamic studies of Fluphenazine Decanoate solubility in propylene glycol + water mixtures and correlation with the Jouyban-Acree model
    Fluid Phase Equilibria, 2011
    Co-Authors: Vahid Panahi-azar, Fleming Martinez, William E Acree, Ali Shayanfar, Abolghasem Jouyban
    Abstract:

    Abstract Solubilities of Fluphenazine Decanoate (FD) in binary mixtures of propylene glycol + water (PG + W) at 293.2, 298.2, 303.2, 308.2, and 313.2 K are reported. The combination of Jouyban–Acree model and van’t Hoff equation is used to predict the solubility of FD in a given solvent mixture at different temperatures. The thermodynamic properties (enthalpy, entropy and Gibbs energy standard changes of solutions) for FD in PG + W mixtures are calculated from solubility data using the modified version of van’t Hoff and Gibbs equations. The results show that Jouyban–Acree model can predict the solubility of FD in PG + W mixtures as a function of temperature over the studied temperature range. The study represents the first time that thermodynamic properties of solutes dissolved in binary solvent mixtures have been described by the Jouyban–Acree model. The calculated values are in good agreement with the measured experimental data.

Walter A Brown - One of the best experts on this subject based on the ideXlab platform.

  • serum neuroleptic levels during reduced dose Fluphenazine Decanoate maintenance therapy
    Israel Journal of Psychiatry and Related Sciences, 1997
    Co-Authors: Uriel Herescolevy, David Greenberg, Bernard Lerer, Daniel C Javitt, Walter A Brown
    Abstract:

    : Forty-one remitted and chronically psychotic schizophrenic out-patients completed a two-year clinical trial during which they were assigned, on the basis of their clinically determined maintenance dosages, to one of two reduced, fixed-dose Fluphenazine Decanoate (FD) regimens: 35 mg/4 wks (19 patients) or 10 mg/4 wks (22 patients). Eighty-one percent of chronically psychotic patients, who represented 74% of the high dose group, relapsed, in comparison with only 38% of remitted patients (p < .001), who represented 86% of the low dose group. During this study serum neuroleptic levels were assessed, using the radioreceptor assay, before the administration of each FD injection and whenever a patient relapsed. Overall, 334 serum neuroleptic activity measurements were performed. Serum neuroleptic levels were detectable in all patients and were higher, although not significantly, in the 35 mg/4 wks group. The dichotomous clinical outcome of chronically psychotic and remitted patients occurred within the framework of essentially similar serum neuroleptic levels. These findings suggest that: 1) serum neuroleptic levels can be monitored during low dose FD treatment, 2) the poor maintenance therapy outcome of chronically psychotic patients cannot be accounted for by inadequate neuroleptic bioavailability, 3) a majority of remitted FD maintained patients retain their clinical response at serum neuroleptic levels lower than those initially attained at steady state.

  • the determination of the steady state pharmacokinetic profile of Fluphenazine Decanoate by gas chromatography mass spectrometry detection
    Schizophrenia Research, 1992
    Co-Authors: William M Glazer, Stephen R Marder, Lawrence T Friedhoff, Walter A Brown
    Abstract:

    Abstract This study uses the highly sensitive method of gas chromatography/mass spectrometry to compare the basic steady-state pharmacokinetic parameters of two Fluphenazine Decanoate formulations. Sixteen stable outpatients participated in a two-way crossover design study of the bioavailability of a new formulation of FPZ Dec, i.e., 10 mg/ml, to the standard 25 mg/ml formulation. When compared to a 1 ml injection of the standard formulation (25 mg/ml) over a two-week, steady-state period, we found bioequivalence as evidenced by similar mean areas under the curve (hrs x ng/ml). We did find that the injection volume of the same dose (2.5 ml of a 10 mg/ml formulation) results in a statistically higher maximum serum level of parent Fluphenazine. A tendency toward faster time to peak level was observed with the 10 mg/ml formulation but the difference was not statistically significant. Both of these differences are considered too small to be clinically significant. In a subgroup of 10 patients, pre-injection serum Fluphenazine levels correlated significantly (Pearson r = 0.78, p

  • The determination of the steady-state pharmacokinetic profile of Fluphenazine Decanoate by gas chromatography/mass spectrometry detection.
    Schizophrenia Research, 1992
    Co-Authors: William M Glazer, Stephen R Marder, Lawrence T Friedhoff, Walter A Brown
    Abstract:

    Abstract This study uses the highly sensitive method of gas chromatography/mass spectrometry to compare the basic steady-state pharmacokinetic parameters of two Fluphenazine Decanoate formulations. Sixteen stable outpatients participated in a two-way crossover design study of the bioavailability of a new formulation of FPZ Dec, i.e., 10 mg/ml, to the standard 25 mg/ml formulation. When compared to a 1 ml injection of the standard formulation (25 mg/ml) over a two-week, steady-state period, we found bioequivalence as evidenced by similar mean areas under the curve (hrs x ng/ml). We did find that the injection volume of the same dose (2.5 ml of a 10 mg/ml formulation) results in a statistically higher maximum serum level of parent Fluphenazine. A tendency toward faster time to peak level was observed with the 10 mg/ml formulation but the difference was not statistically significant. Both of these differences are considered too small to be clinically significant. In a subgroup of 10 patients, pre-injection serum Fluphenazine levels correlated significantly (Pearson r = 0.78, p

Stephen R Marder - One of the best experts on this subject based on the ideXlab platform.

  • Fluphenazine plasma level monitoring for patients receiving Fluphenazine Decanoate.
    Schizophrenia research, 2002
    Co-Authors: Stephen R Marder, Manickam Aravagiri, William C Wirshing, Donna A Wirshing, Malca B Lebell, Jim Mintz
    Abstract:

    Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic plasma levels has the potential for helping clinicians in dosage selection. With this in mind, we evaluated the usefulness of monitoring Fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with Fluphenazine Decanoate. Thirty-one patients with schizophrenia were randomly assigned to low, medium, or high (0.1-0.3, 0.3-0.6, 0.6-1.0 ng/ml) plasma levels of Fluphenazine. The dose of Fluphenazine Decanoate was adjusted in order to maintain patients in their assigned range. Side effects, psychopathology, and psychotic exacerbations were measured during the year following randomization. All of the psychotic exacerbations occurred during the first eight weeks following randomization, before patients had adequate time to reach their plasma level assignments. We did not find a relationship between plasma levels of Fluphenazine and clinical outcomes or side effects. Our results do not provide support for the usefulness of monitoring Fluphenazine plasma levels for patients receiving Fluphenazine Decanoate.

  • Fluphenazine plasma level monitoring for patients receiving Fluphenazine Decanoate
    Schizophrenia Research, 2002
    Co-Authors: Stephen R Marder, Manickam Aravagiri, William C Wirshing, Donna A Wirshing, Malca B Lebell, Jim Mintz
    Abstract:

    Abstract Background: Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to titrate dose against clinical response in patients who are already stable. Therapeutic monitoring of antipsychotic plasma levels has the potential for helping clinicians in dosage selection. With this in mind, we evaluated the usefulness of monitoring Fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with Fluphenazine Decanoate. Method: Thirty-one patients with schizophrenia were randomly assigned to low, medium, or high (0.1–0.3, 0.3–0.6, 0.6–1.0 ng/ml) plasma levels of Fluphenazine. The dose of Fluphenazine Decanoate was adjusted in order to maintain patients in their assigned range. Side effects, psychopathology, and psychotic exacerbations were measured during the year following randomization. Results: All of the psychotic exacerbations occurred during the first eight weeks following randomization, before patients had adequate time to reach their plasma level assignments. We did not find a relationship between plasma levels of Fluphenazine and clinical outcomes or side effects. Conclusion: Our results do not provide support for the usefulness of monitoring Fluphenazine plasma levels for patients receiving Fluphenazine Decanoate.

  • the determination of the steady state pharmacokinetic profile of Fluphenazine Decanoate by gas chromatography mass spectrometry detection
    Schizophrenia Research, 1992
    Co-Authors: William M Glazer, Stephen R Marder, Lawrence T Friedhoff, Walter A Brown
    Abstract:

    Abstract This study uses the highly sensitive method of gas chromatography/mass spectrometry to compare the basic steady-state pharmacokinetic parameters of two Fluphenazine Decanoate formulations. Sixteen stable outpatients participated in a two-way crossover design study of the bioavailability of a new formulation of FPZ Dec, i.e., 10 mg/ml, to the standard 25 mg/ml formulation. When compared to a 1 ml injection of the standard formulation (25 mg/ml) over a two-week, steady-state period, we found bioequivalence as evidenced by similar mean areas under the curve (hrs x ng/ml). We did find that the injection volume of the same dose (2.5 ml of a 10 mg/ml formulation) results in a statistically higher maximum serum level of parent Fluphenazine. A tendency toward faster time to peak level was observed with the 10 mg/ml formulation but the difference was not statistically significant. Both of these differences are considered too small to be clinically significant. In a subgroup of 10 patients, pre-injection serum Fluphenazine levels correlated significantly (Pearson r = 0.78, p

  • The determination of the steady-state pharmacokinetic profile of Fluphenazine Decanoate by gas chromatography/mass spectrometry detection.
    Schizophrenia Research, 1992
    Co-Authors: William M Glazer, Stephen R Marder, Lawrence T Friedhoff, Walter A Brown
    Abstract:

    Abstract This study uses the highly sensitive method of gas chromatography/mass spectrometry to compare the basic steady-state pharmacokinetic parameters of two Fluphenazine Decanoate formulations. Sixteen stable outpatients participated in a two-way crossover design study of the bioavailability of a new formulation of FPZ Dec, i.e., 10 mg/ml, to the standard 25 mg/ml formulation. When compared to a 1 ml injection of the standard formulation (25 mg/ml) over a two-week, steady-state period, we found bioequivalence as evidenced by similar mean areas under the curve (hrs x ng/ml). We did find that the injection volume of the same dose (2.5 ml of a 10 mg/ml formulation) results in a statistically higher maximum serum level of parent Fluphenazine. A tendency toward faster time to peak level was observed with the 10 mg/ml formulation but the difference was not statistically significant. Both of these differences are considered too small to be clinically significant. In a subgroup of 10 patients, pre-injection serum Fluphenazine levels correlated significantly (Pearson r = 0.78, p

  • plasma levels of Fluphenazine in patients receiving Fluphenazine Decanoate relationship to clinical response
    British Journal of Psychiatry, 1991
    Co-Authors: Stephen R Marder, K K Midha, T Van Putten, Manickam Aravagiri, E M Hawes, J W Hubbard, Gordon Mckay, Jim Mintz
    Abstract:

    The levels of Fluphenazine and Fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of Fluphenazine Decanoate every two weeks were monitored. Patients treated with 25 mg of Fluphenazine Decanoate required three months to reach a steady-state plasma level, indicating that those patients who are being converted from oral to depot Fluphenazine should continue to receive oral supplementation during the first three months of treatment with Fluphenazine Decanoate. Plasma levels of Fluphenazine sulphoxide were lower than levels of Fluphenazine. At six and nine months following randomisation, there was a statistically significant relationship between lower Fluphenazine plasma levels and an increased risk of psychotic exacerbations. A relatively weak relationship was found between Fluphenazine plasma levels and akinesia, but non-significant relationships between Fluphenazine levels and other neurological side-effects including akathisia, retardation, and tardive dyskinesia. Monitoring the plasma levels may be helpful to clinicians who are attempting to treat stabilised patients with the lowest effective dose of Fluphenazine Decanoate.

Vahid Panahiazar - One of the best experts on this subject based on the ideXlab platform.

  • solubility of Fluphenazine Decanoate in aqueous mixtures of polyethylene glycols 400 and 600 at various temperatures
    Fluid Phase Equilibria, 2014
    Co-Authors: Abolghasem Jouyban, Fleming Martinez, Vahid Panahiazar
    Abstract:

    Abstract The solubility of Fluphenazine Decanoate (FD) in aqueous binary mixtures of polyethylene glycols 400 (PEG 400) and 600 (PEG 600) at 298.0–318.0 K and atmospheric pressure along with some thermodynamic properties are reported. The previously trained version of the Jouyban–Acree model for PEG 400 + water, a recently proposed general cosolvency model employing partial solubility parameters, and a combination of the model with van’t Hoff equation were used to predict the solubility of FD in PEG 400 + water and PEG 600 + water at different temperatures. The results show that the Jouyban–Acree model can be used for solubility prediction of FD in aqueous mixtures of PEG 400 and PEG 600 at different temperatures. Densities of solute free aqueous mixtures of PEG 400 and PEG 600 along with their FD-saturated solutions are also reported.

  • thermodynamic studies of Fluphenazine Decanoate solubility in peg 200 water mixtures
    Fluid Phase Equilibria, 2012
    Co-Authors: Vahid Panahiazar, Somaieh Ahmadian, Fleming Martinez, William E Acree, Abolghasem Jouyban
    Abstract:

    Abstract The solubility of Fluphenazine Decanoate (FD) in binary mixtures of polyethylene glycol 200 (PEG 200) + water at the temperature range from 298.0 K to 318.0 K is reported. The previously trained version of the Jouyban–Acree model for PEG 200 + water, a recently proposed general cosolvency model employing partial solubility parameters, and a combination of the model with van’t Hoff equation were used to predict the solubility of FD in PEG 200 + water at different temperatures. The results show that the Jouyban–Acree model can be used for solubility prediction of FD in PEG 200 + water mixtures at different temperatures. The solubility data as a function of temperature were used to determine the thermodynamic properties of the dissolution process including Gibbs energy, enthalpy and entropy of the solution. An adapted version of the model is used to represent the thermodynamic properties of the solutions in the solvent mixtures and the obtained results were satisfactory. Densities of solute free PEG 200 + water and FD-saturated solutions are also reported.

  • thermodynamic studies of Fluphenazine Decanoate solubility in propylene glycol water mixtures and correlation with the jouyban acree model
    Fluid Phase Equilibria, 2011
    Co-Authors: Vahid Panahiazar, Fleming Martinez, William E Acree, Ali Shayanfar, Abolghasem Jouyban
    Abstract:

    Abstract Solubilities of Fluphenazine Decanoate (FD) in binary mixtures of propylene glycol + water (PG + W) at 293.2, 298.2, 303.2, 308.2, and 313.2 K are reported. The combination of Jouyban–Acree model and van’t Hoff equation is used to predict the solubility of FD in a given solvent mixture at different temperatures. The thermodynamic properties (enthalpy, entropy and Gibbs energy standard changes of solutions) for FD in PG + W mixtures are calculated from solubility data using the modified version of van’t Hoff and Gibbs equations. The results show that Jouyban–Acree model can predict the solubility of FD in PG + W mixtures as a function of temperature over the studied temperature range. The study represents the first time that thermodynamic properties of solutes dissolved in binary solvent mixtures have been described by the Jouyban–Acree model. The calculated values are in good agreement with the measured experimental data.

Thomas B Cooper - One of the best experts on this subject based on the ideXlab platform.

  • single dose pharmacokinetics of Fluphenazine after Fluphenazine Decanoate administration
    Journal of Clinical Psychopharmacology, 1990
    Co-Authors: George M Simpson, Kashinath G Yadalam, Douglas F Levinson, Mary Jeanne Stephanos, Ee Sing Lo, Thomas B Cooper
    Abstract:

    : Fluphenazine Decanoate is commonly used as part of maintenance treatment of schizophrenia, but its pharmacokinetics are poorly understood. We administered a single intramuscular dose of Fluphenazine Decanoate to nine patients and found that plasma Fluphenazine level did not decline to 50% of the peak level by day 26 in any of the patients. This means that it has a long half-life measurable in months rather than weeks.